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A relatively high rate of vancomycin-resistant Enterococcus faecium not susceptible to linezolid was observed in
intensive care unit patients. Linezolid-resistant isolates carried the G2576T mutation in the 23S rRNA gene,
belonged to different clones, and shared the same allelic profile, which clusters in the C1 multilocus sequence typing
epidemic lineage.
Linezolid, an oxazolidinone antibiotic, was introduced early in
2000 as a new therapeutic option against gram-positive cocci,
including vancomycin-resistant enterococci (VRE). Over the 4-
year period since the beginning of linezolid clinical use, resis-
tance began to emerge, albeit at a very low rate, in clinical
isolates of enterococci (4, 9) and was dependent on prior
linezolid exposure and duration of therapy (10). The molecular
basis of linezolid resistance has been identified as a single
G2576T nucleotide polymorphism in multiple alleles encoding
23S rRNA (7, 8, 11–14).
From January to December 2004, active surveillance of
VRE colonization (stool or rectal swab cultures) was per-
formed on 127 patients admitted to different intensive care
units (ICUs) at the General Hospital of Verona, Verona, Italy
(hospital-wide ICU, neurosurgery ICU, and transplant ICU),
as part of a series of measures to control nosocomial infection
by VRE. All VRE isolated from both colonized and infected
patients were stored for antibiotic susceptibility testing and
molecular characterization.
A total of 35 VRE isolated from the 127 patients were used
in this study. Identification to the species level was performed
by biochemical tests (API; bioMe´rieux). The resistance geno-
type of VRE was identified by PCR using primers specific for
van genes, as described previously (1). Antimicrobial suscep-
tibility was determined by agar diffusion according to the CLSI
(formerly NCCLS) guidelines (2). Enterococcus faecalis ATCC
29212 was used for quality control. The linezolid minimum inhib-
itory concentration (MIC) was determined by Etest (Oxoid).
CLSI MIC interpretative standards for Enterococcus spp.
tested against linezolid were as follows: 2 g/ml for the
susceptible category, 4 g/ml for the intermediate category,
and 8 g/ml for the resistant category. Strain clonality was
analyzed by pulsed-field gel electrophoresis (PFGE), as de-
scribed previously (1). Strains representative of each distinct
PFGE pattern were analyzed by multilocus sequence typing
(MLST), as proposed by Homan et al. (6). Both linezolid-
susceptible (LS) and linezolid-nonsusceptible (LNS) isolates
were analyzed for the presence of the G2576T mutation (ac-
cording to the Escherichia coli numbering system) in the V
domain of the 23S rRNA gene, which generates a new restric-
tion site for NheI (14). An internal fragment (746 bp) of the
23S rRNA gene, including the V domain, was amplified by
PCR in both LS and LNS isolates. Primers designed on the
basis of the sequence of 23S rRNA for Enterococcus faecium
(GenBank accession number AF4329149) were 23Sfor
(5-TAG TAC CTG TGA AGA TGC AGG-3) and 23Srev
(5-CAC ACT TAG ATG CTT TCA GCG-3). The cycling
conditions were as follows: an initial denaturation at 94°C for
5 min, followed by 30 cycles consisting of 94°C for 1 min, 50°C
for 30 s, 72°C for 1 min, and a final extension step at 72°C for
5 min. Small amounts (5 l) of PCR 23S rRNA were digested
with 10 units of NheI (Invitrogen Life Technologies) at 37°C
for 4 h and separated on 2% agarose gel in 1 Tris-acetate-
EDTA buffer. To confirm the G2576T point mutation, an
allele-specific PCR assay was used in which total DNA was
subjected to two distinct PCRs with primers specific for the
wild type and mutant (7). The specificities of both reactions
were assessed by testing 35 LS vancomycin-resistant E. faecium
(VREF) strains with the same procedures. Sequencing of the
internal fragment of the 23S rRNA gene obtained by PCR was
also done to confirm the G2576T mutation.
Of the 127 patients admitted to different ICUs at the Gen-
eral Hospital of Verona, 29 (22.8% colonization rate) were
positive for VRE (24 for E. faecium, 3 for Enterococcus galli-
narum, 1 for E. faecalis, and 1 for Enterococcus avium). Ten
patients developed clinically significant infections caused by VRE
(7.4% infection rate); six of these did not present concurrent stool
colonization.
Of the 35 VRE infected/colonized patients, 14 carried LNS
VREF. Eight of these patients harbored strains with interme-
diate susceptibility (MIC  4 g/ml), and six harbored resis-
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tant strains (MIC 8 g/ml). Table 1 gives the clinical data for
the six patients infected by linezolid-resistant (LR) VREF. The
criteria for active infection as listed by the Centers for Disease
Control and Prevention (3) were met for the patients from
whom the strains were isolated. In all, one linezolid-interme-
diate (LI) isolate and nine LR isolates were recovered and
analyzed (Table 1). Five of the six patients were infected by LR
VREF (MIC  8 g/ml), and one was initially infected by a
VRE with intermediate susceptibility to linezolid which devel-
oped resistance during linezolid therapy. All strains were resistant
to vancomycin and teicoplanin, to ampicillin, and to high concen-
trations of gentamicin and streptomycin; all were susceptible to
quinupristin-dalfopristin; and all carried the vanA gene.
Four prevalent PFGE types were identified among these
FIG. 1. Digestion of 746-bp 23S rRNA obtained by PCR with NheI and separated on 2% agarose gel in 1 Tris-acetate-EDTA buffer. Lane
1, X174 replicative-form DNA/HaeIII molecular mass standard; lanes 2 and 4, linezolid-susceptible strains SM888 and SM913 (MIC, 2 g/ml);
lanes 3 and 5, strains SM912 and SM925 (MIC, 8 g/ml); lanes 6 and 7, strains SM943 and SM944 (MIC, 64 g/ml).
TABLE 1. Clinical data of patients infected or colonized by linezolid-resistant E. faecium and molecular typing of linezolid-resistant isolates
Patient
(sex/age [yr]) Ward
a Underlying
disease(s) Risk/outcome
b Strain
code
Type or site of
infection
(isolation date
[mo/day/yr])
Linezolid
MIC
(g/ml)
PFGE
typec
MLST
type
Detection
of G2576
mutation
Detection
of T2576
mutation
P1 (male/64) TICU Kidney
transplant
Prolonged hospitalization
(58 days), ICU care,
linezolid use,
discharged
SM902 Ascites (03/25/04) 4 (LI) D04 78 Yes No
SM912 Ascites (05/05/04) 8 (LR) D04 Yes Yes
P2 (female/71) NICU Communicans
artery
aneurysm
Prolonged hospitalization
(81 days), ICU care,
linezolid use,
discharged
SM922 Urine (07/12/04) 8 (LR) C04 78 Yes Yes
SM924 Rectal (07/13/04) 8 (LR) C1,04 Yes Yes
SM925 Rectal (07/21/04) 8 (LR) C04
P3 (female/64) ICU Ictus, diabetes Died after 8 days of
hospitalization
SM941 Rectal (10/19/04) 8 (LR) F04 78 Yes Yes
P4 (female/75) NICU Communicans
artery
aneurysm
Prolonged hospitalization
(56 days), ICU care,
discharged
SM934 Rectal (09/22/04) 64 (LR) A*2n,04 78 Yes Yes
P5 (male/74) ICU Necrotizing
pancreatitis
Prolonged hospitalization
(46 days), ICU care,
linezolid use, death
SM943 Ascites (11/02/04) 64 (LR) A*2.04 78 Yes Yes
P6 (male/67) ICU Spontaneous
esophageal
rupture,
mediastinitis,
peritonitis
Hospitalization
overlapping P5, ICU
care, discharged
SM936 Rectal (10/01/04) 64 (LR) A*2.04 78 Yes Yes
SM944 Ascites (11/18/04) 64 (LR) A*2.04 Yes Yes
a ICU, hospital-wide intensive care unit; TICU, transplant ICU; NICU, neurosurgery ICU.
b Time elapsing from date of admission to date of isolation of first LR VREF in body samples is shown in parentheses.
c * indicates the PFGE type of the index strain (SM685) of nosocomial outbreaks in northern Italy (1).
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strains (Table 1). One strain representative of each distinct
PFGE pattern was typed by MLST, and all were found to
belong to the same sequence type, 78, as that of the reference
strain E. faecium SM685, representative of strains which
caused nosocomial outbreaks in several hospitals in northern
Italy from 2000 to 2001 (1).
The G2576T point mutation was detected only in strains
with linezolid MICs of 8 g/ml. Figure 1 shows the results of
NheI digestion of the PCR amplicons from the V domain of
the 23S rRNA gene. The 746-bp band corresponding to the
undigested amplification products and the two bands of 557 bp
and 189 bp corresponding to the two products of NheI diges-
tion were found in all LR VRE, suggesting that both wild-type
and mutant alleles were present in the same strain. The higher
density of the 746-bp band in strains with MICs of 8 g/ml
suggested a lower copy number of the mutated gene in these
strains than that in strains with MICs of 64 g/ml. The pres-
ence of the G2576T point mutation in linezolid-resistant
strains was confirmed by allele-specific PCR and by sequencing
the internal fragment of the 23S rRNA gene obtained by PCR
(not shown).
The emergence of LR VRE has been reported in several
studies, but overall, it is considered to be uncommon (9). Thus,
the finding of a high rate of linezolid nonsusceptibility in
VREF isolated from patients in the ICUs of our institution is
quite alarming. Our data, combined with the clinical descrip-
tions, suggest different modalities of acquisition of LR VREF:
(i) an independent event of de novo selection of resistant
mutants in colonizing/infecting VREF (patients P1, P2, and P3,
who carried genetically unrelated strains), (ii) possible patient-
to-patient spread (patients P4, P5, P6, who carried genetically
related strains), and (iii) emergence of linezolid-resistant mu-
tants from LI VRE during linezolid therapy (patient P1).
In our patients, the risk factors for LNS VRE infections
were the same as those described for LS VRE (10): prolonged
hospitalization, serious underlying diseases, multiple cycles of
antibiotic treatments, etc. However, in one case (patient P3),
none of these risk factors were present. The patient, colonized
by an LR VREF with a unique PFGE type, was a 64-year-old
female living at home with no hospitalization over the previous
10 years and no antibiotic treatment during the past year.
Patient P6 did not receive linezolid therapy but had other risk
factors, including overlapping hospitalization with patient P5,
who was treated with linezolid for 3 weeks.
Clinical microbiology laboratories should be aware of the
emergence of resistance and should test appropriate isolates
for susceptibility to linezolid. CLSI breakpoints for enterococci
should be carefully applied, and strains with intermediate sus-
ceptibility (MIC  4 g/ml) should be considered at the risk of
developing LR under antibiotic selective pressure. The case
(patient P1) of selection of LR VREF during therapy in a
patient infected by an LI VREF who apparently did not carry
the point mutation strongly suggests the possibility that the
molecular assay we used was not sufficiently sensitive to detect
a low number of copies of the mutated allele. In a study based
on pyrosequencing of 23S rRNA genes, the occasional detec-
tion of the G2576T mutation in strains with an MIC of 4 g/ml
has been reported (13).
The high rate of LNS VREF we found in our institution is
suggestive of an increasing resistance rate trend that could
limit the clinical use of linezolid in the near future. Also in-
triguing is the fact that all the LR VREF strains belonged to
the MLST C1 sublineage that has been emerging recently
worldwide and includes isolates mainly from human infections
and hospital outbreaks (1, 6). Acquisition of linezolid resis-
tance is the latest disturbing conquest of this lineage and would
limit the range of effective therapies available for various life-
threatening infections.
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